An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
NCT ID: NCT05959070
Last Updated: 2025-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
154 participants
OBSERVATIONAL
2023-11-09
2025-03-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03982394
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT07039110
Assessment of Long-Term Infliximab for Psoriasis (P05319)
NCT00779675
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
NCT04713592
Subclinical Impairment of Cardiovascular System in Patients With Psoriasis
NCT05957120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risankizumab
Participants will receive risankizumab as prescribed by their physician according to local label.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants initiating RZB treatment for psoriasis as per local label. Physician's decision for treatment with risankizumab must have been reached prior to and independently of recruitment in the study.
* Participants able to understand and communicate with the investigator and comply with the requirements of the study.
* Willingness and ability to comply with all study requirements.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universite Libre de Bruxelles - Hopital Erasme /ID# 252456
Anderlecht, Brussels Capital, Belgium
Cliniques Universitaires UCL Saint-Luc /ID# 253234
Brussels, Brussels Capital, Belgium
UZ Gent /ID# 252458
Ghent, Oost-Vlaanderen, Belgium
Dermatologie Maldegem /ID# 252454
Maldegem, Oost-Vlaanderen, Belgium
Universitair Ziekenhuis Leuven /ID# 252457
Leuven, Vlaams-Brabant, Belgium
Wiseman Dermatology Research /ID# 255883
Winnipeg, Manitoba, Canada
Dermatrials Research /ID# 253879
Hamilton, Ontario, Canada
Lynde Institute for Dermatology /ID# 253876
Markham, Ontario, Canada
JRB Research /ID# 253877
Ottawa, Ontario, Canada
SKiN Centre for Dermatology /ID# 255882
Peterborough, Ontario, Canada
Dre Angelique Gagne-Henley M.D. inc. /ID# 262591
Saint-Jérôme, Quebec, Canada
Hautarztpraxis Mortazawi /ID# 255872
Remscheid, North Rhine-Westphalia, Germany
Dermatologische Praxis Dr. med. Marvin Kuske /ID# 265688
Dresden, , Germany
Universitaetsklinikum Hamburg-Eppendorf /ID# 254340
Hamburg, , Germany
Gemeinschaftspraxis Dres. Anika Hünermund/Mario Pawlak /ID# 255874
Heilbad Heiligenstadt, , Germany
Praxis Dres. Wiemers/Wiemers /ID# 255873
Leipzig, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P23-435
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.